Market Forecast South Korean Pharma Market to Grow by 16 %

Author / Editor: Ahlam Rais / Wolfgang Ernhofer

Onsite survey results at CPhI Korea reveal a few stunning predictions for the region’s pharma sector. In addition to this, the government’s initiatives towards the development of the sector was also appreciated by industry players.

Related Vendors

Domestic companies predict a 16% growth in the South Korean pharma market during CPhI Korea.
Domestic companies predict a 16% growth in the South Korean pharma market during CPhI Korea.
(Source: Deposit Photo)

Amsterdam/The Netherlands – CPhI Korea has recently closed its doors in Seoul after another record-breaking event that attracted 4,300 attendees and 147 exhibitors. During the event, UBM, the organizer undertook an in-depth onsite survey of both international and domestic attendees, with domestic companies reporting a headline growth in the order of 16 % across the South Korean pharma economy.

As one of the largest pharma events in South Korea, the confidence amongst the attendees is a good indication of the industry’s overall health. And, the onsite survey results showed that 75 % of domestic companies believe that the South Korean ‘biologics and biosimilars sectors will grow the fastest’. However, just 44.5 % of international companies agreed with this, with 30 % stating generics had the biggest potential.

Highlighting the positive impact the Incheon Free Economic Zone has had on the industry, 95 % of all respondents backed the government introducing ‘further similar incentives’. International respondents were also complimentary of government initiatives to position the country as a biotech leader. Over 85 % of them agreed that ‘Bio-Vision 2016’ had been very successful and made good strides in achieving the goal of becoming a trusted market frontrunner. Conversely, a diametric result was observed domestically as only 33 % of respondents saw the initiative as a success.

International partnerships are quickly becoming a driving force for South Korea’s pharma sector. Highlighting this, over 95% of the international companies surveyed, reported they are looking to work with South Korean partners in the next year, and 43 % of domestic respondents have undertaken work in international markets.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent